Identification of Protein Kinase Inhibitors with a Selective Negative Effect on 
the Viability of Epstein-Barr Virus Infected B Cell Lines

Mavromatidis, Vassilis; Varga, Zoltan; Waczek, Frigyes; Örfi, Zoltán; Örfi, Laszlo; Keri, Gyoergy; Mosialos, George

doi:10.1371/journal.pone.0095688

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Identification of Protein Kinase Inhibitors with a Selective Negative Effect on the Viability of Epstein-Barr Virus Infected B Cell Lines

MPS-Authors

/persons/resource/persons130612

Örfi, Zoltán
Ullrich, Axel / Molecular Biology, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

journal.pone.0095688.pdf
(Any fulltext), 2MB

Supplementary Material (public)

There is no public supplementary material available

Citation

Mavromatidis, V., Varga, Z., Waczek, F., Örfi, Z., Örfi, L., Keri, G., et al. (2014). Identification of Protein Kinase Inhibitors with a Selective Negative Effect on the Viability of Epstein-Barr Virus Infected B Cell Lines. PLOS ONE, 9(4): e95688. doi:10.1371/journal.pone.0095688.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0019-CEDC-6

Abstract

Epstein-Barr virus (EBV) is a human herpesvirus, which is causally associated with the development of several B lymphocytic malignancies that include Burkitt's lymphomas, Hodgkin's disease, AIDS and posttransplant associated lymphomas. The transforming activity of EBV is orchestrated by several latent viral proteins that mimic and modulate cellular growth promoting and antiapoptotic signaling pathways, which involve among others the activity of protein kinases. In an effort to identify small molecule inhibitors of the growth of EBV-transformed B lymphocytes a library of 254 kinase inhibitors was screened. This effort identified two tyrosine kinase inhibitors and two MEK inhibitors that compromised preferentially the viability of EBV-infected human B lymphocytes. Our findings highlight the possible dependence of EBV-infected B lymphocytes on specific kinase-regulated pathways underlining the potential for the development of small molecule-based therapeutics that could target selectively EBV-associated human B lymphocyte malignancies.